Figure 2From: Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reductionFibrates trials as an example of a dilution effect in epidemiology: strong significant cardiovascular risk reduction in patients with atherogenic dyslipidemia[46], non significant effect in those without dyslipidemia[46]and a blended modest effect in the mixed “general population”[47].Back to article page